Last updated: January 29, 2026
Sponsor: AbbVie
Overall Status: Planned
Phase
N/A
Condition
Multiple Myeloma
Cancer/tumors
Lymphoproliferative Disorders
Treatment
Venetoclax
Clinical Study ID
NCT03123029
C16-431
C20-485
C19-920
All Genders
Study Summary
Eligibility Criteria
Inclusion
Exclusion Criteria:
There are other suitable treatment options.
The participant qualifies for ongoing clinical trials.
Study Design
Treatment Group(s): 1
Primary Treatment: Venetoclax
Phase:
Study Start date:
Estimated Completion Date: